ANTI — Antigenics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for Antigenics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
1996 December 31st | 1997 December 31st | 1998 December 31st | 1999 December 31st | 2000 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K405 | 10-K405 | 10-K405 | 10-K |
| Standards: | — | — | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Other Revenue | |||||
| Total Revenue | 2.67 | 0.841 | 6.74 | 11.1 | 3.22 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.2 | 19.6 | 26.1 | 26.1 | 19.9 |
| Operating Profit | -9.55 | -18.8 | -19.4 | -15.1 | -16.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.03 | -17 | -18.2 | -14.1 | -13.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.03 | -17 | -18.2 | -14.1 | -13.5 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -8.03 | -17 | -18.2 | -14.1 | -18 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -8.03 | -17 | -18.2 | -14.1 | -18 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.597 | -0.939 | -1.17 | -0.649 | -0.543 |
| Dividends per Share |